TAVOCEPT
Live / Applied — Third extension granted (statement of use) (as of 09 Jan 2026)
What this means for you
Not registered yet, but its 19 Jul 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97510148
- Mark type
- Stylized text
- Filed
- 19 Jul 2022
- Published for opposition
- 14 May 2024
- Attorney of record
- Nigamnarayan Acharya
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, medications used in chemotherapeutic regimens for the treatment of cancer; pharmaceutical preparations for the treatment of cancer
Owner
- Lantern Pharma Inc., Dallas, TX, US
- Lantern Pharma Inc., Dallas, TX, US
Prosecution history
- 10 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jan 2026 — SOU EXTENSION 3 GRANTED
- 09 Jan 2026 — SOU EXTENSION 3 FILED
- 09 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 10 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jul 2025 — SOU EXTENSION 2 GRANTED
- 09 Jul 2025 — SOU EXTENSION 2 FILED
- 09 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 27 May 2025 — SOU EXTENSION 1 GRANTED
- 08 Jan 2025 — SOU EXTENSION 1 FILED
- 27 May 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 07 Apr 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 07 Apr 2025 — NOTICE OF REVIVAL - E-MAILED
- 07 Apr 2025 — PETITION TO REVIVE-GRANTED
- 07 Apr 2025 — TEAS PETITION TO REVIVE RECEIVED